-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23

Benzinga·05/11/2026 11:51:18
Listen to the news
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.